Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650495 | 0.81 | BRD4 (0.38) | MAPTCREBBPGLAL3MBTL1KDM4E | |
| SCHEMBL20366362 | 0.80 | POLB (0.35) | CREBBPMEN1KMT2ABRD4BRD9 | |
| SCHEMBL21904918 | 0.73 | CREBBP (0.39) | CREBBPMEN1KMT2ABRD4BRD9 | |
| SCHEMBL24556490 | 0.69 | BRD4 (0.37) | KDM4EBRD4 | |
| SCHEMBL23963560 | 0.69 | — | — | |
| SCHEMBL3374696 | 0.68 | MAP2K1 (0.45) | CREBBPGLAL3MBTL1KDM4EMEN1 | |
| SCHEMBL17810138 | 0.68 | MEN1 (0.37) | MAPTGLAL3MBTL1KDM4EMEN1 | |
| SCHEMBL18496282 | 0.68 | CREBBP (0.35) | CREBBPL3MBTL1BRD4LMNABRD9 | |
| SCHEMBL24556399 | 0.67 | BRD4 (0.36) | BRD4 | |
| SCHEMBL16652102 | 0.67 | BRD4 (0.47) | MEN1KMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | MAPT 2462/4885CREBBP 45/4885GLA 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.